Amgen
6/10
Amgen carries $54.6B in long-term debt, with $56.0B in scheduled principal maturities. AMGN shows a debt-to-equity ratio of 6.3x — well above the typical threshold for financial stress. DebtCanary scores AMGN at 6/10, indicating moderate refinancing pressure.
Maturity Schedule
| Period | Amount Due |
|---|---|
| Year 1 (0-12 months) | $4.6B |
| Year 2 (12-24 months) | $2.7B |
| Year 3 (24-36 months) | $5.0B |
| Year 4 (36-48 months) | $2.9B |
| Year 5 (48-60 months) | $4.0B |
| Beyond 5 Years | $36.8B |
| Total Scheduled Maturities | $56.0B |
Key Metrics
Score Components
| Component | Value |
|---|---|
| Near-Term Maturity Concentration | 8.2% |
| Interest Coverage Ratio | N/A |
| Debt-to-Equity Ratio | 6.31 |
| Cash Coverage of Near-Term Debt | 2.00x |
Recent SEC Filings
Material disclosures from Amgen's most recent EDGAR filings. 8-K item labels indicate the type of event reported.
| Date | Form | Details |
|---|---|---|
| 2026-04-22 | 8-K | Officer / Director Change |
| 2026-04-21 | DEFA14A | Additional proxy materials |
| 2026-04-15 | DEFA14A | Additional proxy materials |
| 2026-04-07 | DEFA14A | Additional proxy materials |
| 2026-04-07 | DEF 14A | Proxy statement |
| 2026-02-19 | 8-K | Material Agreement |
| 2026-02-19 | 424B2 | Prospectus supplement — possible debt or equity issuance |
| 2026-02-17 | 424B3 | Prospectus supplement — possible debt or equity issuance |
Related Companies
Data Source:
Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports).
Fiscal period end: 2025-12-31.
Filing date: 2026-02-13.
Data last fetched: 2026-04-29.
Maturity schedules reflect the company's most recently reported debt repayment obligations.
Data quality: Partial.
View SEC EDGAR filings for Amgen →